Registered users receive a variety of benefits including the ability to customize email alerts, create favorite journals list, and save searches.
Please note that a BioOne web account does not automatically grant access to full-text content. An institutional or society member subscription is required to view non-Open Access content.
Contact helpdesk@bioone.org with any questions.
The effects of glutamine supplementation on the blastocoele formation and hatching of mouse preimplantation embryos were investigated. When culturing the 1-cell or 2-cell stage embryos in glutamine-supplemented media, the incidence of development to each stage from the morula stage to the completely hatched blastocyst stage was higher than for culturing in media without glutamine supplementation. When culturing 4-cell stage, 8-cell stage or morula stage embryos in glutamine-supplemented media, percentage of development up to the expanded blastocyst stage was comparable to culturing in media without glutamine supplementation, but the hatching rate for the glutamine-supplemented media was higher or tended to be higher compared to culturing in media without glutamine supplementation. Further, culturing in glutamine-supplemented media from the early blastocyst stage, the blastocyst stage or the expanded blastocyst stage resulted in a higher hatching rate compared to culturing in media without glutamine supplementation. These findings suggest that culturing in glutamine-supplemented media before the 2-cell stage, leads to improvements not only in the rates of morula formation and blastocoele formation, but also the rate of hatching. Further, efficient usage of glutamine appears to be elevated during the course of hatching.
In the United States, assisted reproduction devices are categorized as “medical devices” and regulated by FDA. Most of assisted reproduction devices are classified in Class II based on level of control necessary to assure the safety and effectiveness as well as on risk to patient and/or user. Manufactures must submit a 510(k) to FDA before introducing a device to the U. S. market. Assisted Reproduction devices should be manufactured in accordance with Good Manufacturing Practice (GMP) and manufactures must demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. The status of regulations and the contents required to applicants in the U. S. are reported.
This article is only available to subscribers. It is not available for individual sale.
Access to the requested content is limited to institutions that have
purchased or subscribe to this BioOne eBook Collection. You are receiving
this notice because your organization may not have this eBook access.*
*Shibboleth/Open Athens users-please
sign in
to access your institution's subscriptions.
Additional information about institution subscriptions can be foundhere